Press releases

Release issued 5th November 2010

 
One Nucleus presents Life Science Leadership Series: For Partnering, For Dealflow
Cambridge, 4 November 2010 - One Nucleus, the not-for-profit membership company for international life science and healthcare companies, is to launch a series of high level conferences focused on specific technology areas, replacing its annual BioPartnering Exchange conference. The move comes in response to member feedback and aims to deliver a more tailored and focused conference experience.
While ERBI and the Cambridge Summer Bio-Partnering Exchange conference were trail-blazers in the last decade, the landscape has changed dramatically.  Greater international collaboration and dealflow have created many global biopartnering events of varying size and quality. The investment climate has moved from domination by venture finance to a combination of public and corporate venture funding and the pressure for capital efficiency to access deals, investment and knowledge has never been greater.
Following the merger of ERBI with the London Biotechnology Network in May 2010 to form One Nucleus, feedback from members as well as pharma and investors has indicated that the ‘now generic' model of membership organisations delivering expensive broad-spectrum biopartnering conferences is now less fit for purpose.
Harriet Fear, CEO of One Nucleus, said: "We feel it is time to leave the larger forums to for-profit organisers, and use the resources to deliver top quality, well focused events that provide debate and deal flow opportunities."
Each of the new series of day-long conferences will focus on a particular technology area (initially oncology; healthcare technology and CNS/Ageing for 2011 and early 2012).The programmes will include world-leading plenary speakers on the future direction of medical need, regulation and investment opportunities, speakers showcasing of enabling technology platforms, One-to-One partnering, and an enhanced networking opportunity with delegates aligned to the focus area. The programme will also include exhibition opportunities for academia and company posters showcasing licencing opportunities and research. And there will be a far lower fee for delegates compared to the traditional bio-partnering format.
To see the One Nucleus leadership matrix please click here. Details of the programme and venue for the first in the series will issue shortly.
For further information please contact Tony (tony@onenucleus.com) or Harriet (harriet@onenucleus.com).

(1st April 2011) Leaders in oncology drug discovery, development and investment converge on Cambridge - 12 May 2011

(4th January 2011) ONE NUCLEUS SIGNS AGREEMENT WITH BIONOW TO EXPAND ACCESS TO ONE NUCLEUS PREFERRED SUPPLIERS

(18th October 2010) Genesis Conference on target to exceed all previous years